Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NXniSFhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHaemZ{UUN3ME21Mlg3PjZizszN NFLmdGNUSU6JRWK=
DOHH-2 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\LTWM2OD17LkO1Olg6KM7:TR?= NVPqWlRxW0GQR1XS
no-10 NF:y[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfCTXM6UUN3ME25MlkxOzlizszN MlPUV2FPT0WU
LS-513 M2PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rVe2lEPTB;MUGuN|U1PyEQvF2= NFjKT4lUSU6JRWK=
ALL-PO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:1RZZTUUN3ME2xNU44PzN2IN88US=> M{fEfXNCVkeHUh?=
8-MG-BA NFn3eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LGPGlEPTB;MUOuNVEzOyEQvF2= NV;BU25GW0GQR1XS
RPMI-8402 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;6TWM2OD1zNT64OVM4KM7:TR?= MWXTRW5ITVJ?
EoL-1-cell MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnKTWM2OD1zOD61PVQ5KM7:TR?= NHPScpdUSU6JRWK=
NALM-6 NXHzPHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPrblFGUUN3ME2xPU4xOTZ5IN88US=> NXraUHQ1W0GQR1XS
DEL NXK0SFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H0UmlEPTB;MkCuNVQ4OSEQvF2= M3jTNHNCVkeHUh?=
SR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDCXmtKSzVyPUKzMlY4OTVizszN NXHtPG9{W0GQR1XS
697 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ4Lk[xOVUh|ryP MUDTRW5ITVJ?
COLO-829 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXJTHlPUUN3ME2yOk45PDh|IN88US=> NEXQW3FUSU6JRWK=
EVSA-T NVP0RWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn3cphIUUN3ME2yO{42PTZzIN88US=> MmLHV2FPT0WU
ATN-1 NULQ[W5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PncGlEPTB;M{GuNlMzQSEQvF2= NGjybHJUSU6JRWK=
L-363 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfRbYtKSzVyPUOxMlc1PjFizszN MUXTRW5ITVJ?
LAMA-84 NIq0W3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrQTXJpUUN3ME2zNk42OjFzIN88US=> MkDwV2FPT0WU
NOS-1 NU\wWnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN2LkK5OVYh|ryP MVPTRW5ITVJ?
BB30-HNC M2X6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HoOmlEPTB;M{SuN|MxPiEQvF2= MlTQV2FPT0WU
BC-1 NHS1eG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jpXWlEPTB;M{euPVc1PiEQvF2= NFzScnNUSU6JRWK=
IST-SL2 M4DOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXYTWM2OD1|OD6yNlQh|ryP MVLTRW5ITVJ?
D-392MG NWL1T5g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjFNpJXUUN3ME20NE4zOjF3IN88US=> MWPTRW5ITVJ?
no-11 NYDoXIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXrcopuUUN3ME20NE42PTJzIN88US=> MYHTRW5ITVJ?
LC4-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33TUWlEPTB;NECuPFcyPiEQvF2= NYLvVFVRW0GQR1XS
A388 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHtTWM2OD12Mj61PFQ5KM7:TR?= MVzTRW5ITVJ?
NTERA-S-cl-D1 NHXBdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR{LkewO|Qh|ryP M1nFcXNCVkeHUh?=
CESS M2nTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP4VW5VUUN3ME20OE4zOjN{IN88US=> M4fwcHNCVkeHUh?=
RS4-11 NETpXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LBdmlEPTB;NEmuNFk{QCEQvF2= MUHTRW5ITVJ?
MS-1 M3\yRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XNfWlEPTB;NUCuPVM2OSEQvF2= MkDoV2FPT0WU
CTV-1 NXz1UoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLSlVtUUN3ME21NU4xPzRizszN M1HESXNCVkeHUh?=
D-502MG MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD13MT62NlcyKM7:TR?= NFzu[4NUSU6JRWK=
ML-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTV{LkmxPVUh|ryP NHTNSHRUSU6JRWK=
SK-NEP-1 NH;BVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKyPVFKSzVyPUWzMlM6OjNizszN NYTRdFBzW0GQR1XS
LOXIMVI M3HYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTV|LkW4PFQh|ryP NVLOXWJFW0GQR1XS
DJM-1 M1XDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf3b5VKSzVyPUW2MlM{QTFizszN M1GxVHNCVkeHUh?=
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjZWWVKSzVyPUW2MlYyPDlizszN NF7mSVJUSU6JRWK=
IST-MES1 NUDhe405T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTXTWM2OD14MD61OFk{KM7:TR?= MUnTRW5ITVJ?
MV-4-11 NV\MRZliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XE[2lEPTB;NkCuOlU{QCEQvF2= NV3UTppiW0GQR1XS
OVCAR-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTZ|LkW2OVch|ryP MWHTRW5ITVJ?
KE-37 M4rPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPWVXRKSzVyPU[2MlI3PjhizszN M1u1N3NCVkeHUh?=
D-542MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;VeVJuUUN3ME22PE41OTN3IN88US=> NYDDTmRJW0GQR1XS
MHH-PREB-1 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTd{Lki0OFEh|ryP M{fuPHNCVkeHUh?=
MRK-nu-1 NITtb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTd|LkS3NFUh|ryP MXrTRW5ITVJ?
D-247MG NVnxPHhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW2foVoUUN3ME23N{42PDR{IN88US=> NXrmfnloW0GQR1XS
OCI-AML2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X4RWlEPTB;N{[uPVM3QSEQvF2= NULCOFd2W0GQR1XS
LP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpTWM2OD16Mj64O|MyKM7:TR?= NV7lflU1W0GQR1XS
HCC1599 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLFTWM2OD16ND6yPFM4KM7:TR?= NV;lSGdoW0GQR1XS
KARPAS-45 NEHJc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGzUoVKSzVyPUi0MlY6QTJizszN M2\RTnNCVkeHUh?=
BE-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LiXWlEPTB;OUmuNFQ4PyEQvF2= NY\I[FRnW0GQR1XS
GCIY NWXUdWFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3PZXZKSzVyPUm5MlA6PTRizszN NXvROphkW0GQR1XS
BV-173 NWjzNXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHtTWM2OD1zMECuN|I2KM7:TR?= Mmr5V2FPT0WU
LB2518-MEL MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfaTWM2OD1zMECuO|g6KM7:TR?= MXHTRW5ITVJ?
KS-1 NEDLfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvVO4VKUUN3ME2xNFEvPjN7IN88US=> Mm\qV2FPT0WU
MOLT-16 MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHKZWRKSzVyPUGwOE46QDZizszN M{nzN3NCVkeHUh?=
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\GVG1KSzVyPUGwPE44QDRizszN NXXmUYFuW0GQR1XS
NCI-H82 M13vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGzVnlKUUN3ME2xNVAvQTd4IN88US=> MULTRW5ITVJ?
NCCIT MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfxTWM2OD1zMUKuOVI6KM7:TR?= NWfwc5V3W0GQR1XS
KALS-1 M1HsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFzNT65OFEh|ryP NI\OU5JUSU6JRWK=
LB2241-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLieVVKSzVyPUGxOk43PzlizszN MojBV2FPT0WU
HH MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzNz6zPVUh|ryP MXzTRW5ITVJ?
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XS[WlEPTB;MUG4MlQ5QCEQvF2= MYDTRW5ITVJ?
EB-3 NEnIW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3WO5l1UUN3ME2xNlMvODl2IN88US=> NUXmT2lGW0GQR1XS
BL-70 NFvuPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF{Mz6xNlch|ryP MYfTRW5ITVJ?
K-562 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLVTWM2OD1zMk[uNlQ2KM7:TR?= NU\DXohMW0GQR1XS
HT-144 NWr2foNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq5TWM2OD1zM{OuNVY1KM7:TR?= MXrTRW5ITVJ?
PF-382 NH64WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzOZlNKSzVyPUGzOE4{PjFizszN MWXTRW5ITVJ?
RPMI-8226 M1q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF|NT6wOFUh|ryP NInD[oxUSU6JRWK=
NCI-H1355 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2[HdKSzVyPUGzOU42QDdizszN MmjOV2FPT0WU
LXF-289 NVG3SVRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW3TWM2OD1zM{muO|gyKM7:TR?= MUDTRW5ITVJ?
NCI-H69 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlztTWM2OD1zNEKuPVMzKM7:TR?= MlPoV2FPT0WU
SK-MEL-1 NULZ[HJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPQNGNKSzVyPUG0O{4yOyEQvF2= MXvTRW5ITVJ?
KARPAS-299 NEHRcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\OPG9KSzVyPUG0PU4yOiEQvF2= M17Hd3NCVkeHUh?=
GB-1 NUS0d2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K3XWlEPTB;MUS5MlMzOiEQvF2= Mom0V2FPT0WU
CMK M2j0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrHUINKSzVyPUG0PU42OTVizszN NX\ISHdXW0GQR1XS
MPP-89 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rFNmlEPTB;MUW2MlA{PSEQvF2= NXHZSpFZW0GQR1XS
KU812 NULvbIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zsOmlEPTB;MU[xMlkxOiEQvF2= NYH5N5F2W0GQR1XS
REH NUL4V21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TpVGlEPTB;MU[yMlEzPSEQvF2= M361b3NCVkeHUh?=
NEC8 NFnQXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHkeZJKSzVyPUG2OU4xOjZizszN M4TRU3NCVkeHUh?=
KP-N-YS M1vB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTLTWM2OD1zNkiuN|k2KM7:TR?= MoXXV2FPT0WU
Ramos-2G6-4C10 NFPyeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK5Z21IUUN3ME2xOlkvQTF3IN88US=> NHTVbXBUSU6JRWK=
Becker NIPm[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\GSnlKSzVyPUG3OE4yQCEQvF2= MYXTRW5ITVJ?
LB647-SCLC M{DLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PnNGlEPTB;MUe1Mlg1PSEQvF2= M2LVNXNCVkeHUh?=
LU-139 NXW1[2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PDcmlEPTB;MUe4MlAyQSEQvF2= MkfTV2FPT0WU
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF5OT62OFYh|ryP NHizTHpUSU6JRWK=
NCI-H1395 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF5OT65PVYh|ryP Mo\RV2FPT0WU
NOMO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3TmlEPTB;MUiyMlg2KM7:TR?= MWTTRW5ITVJ?
GI-ME-N MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TxRmlEPTB;MUi3Mlk3QSEQvF2= NWjKb4VYW0GQR1XS
KMS-12-PE NFvUTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6wVmlKSzVyPUG4PU4zPzNizszN NHvtXmNUSU6JRWK=
Daudi MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQ[mZKSzVyPUG5NU4yOjhizszN NVm5TnNJW0GQR1XS
LB996-RCC MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF7MT62PVkh|ryP Mn73V2FPT0WU
NCI-H2107 NUjoVpZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF7Mz63N|kh|ryP M4fvOHNCVkeHUh?=
SK-PN-DW NH\FbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrJZYNKSzVyPUG5OE44OTlizszN MULTRW5ITVJ?
MC-CAR NF3xWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICzTWhKSzVyPUKwNk4zPTNizszN MVzTRW5ITVJ?
SNB75 M3vrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfVTWM2OD1{MkGuPVQh|ryP NYr3WHExW0GQR1XS
ES4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3LPGNKSzVyPUKyN{44QDNizszN NGjYRVNUSU6JRWK=
KARPAS-422 NG[1S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HEcmlEPTB;MkK4MlM2OiEQvF2= M3vHN3NCVkeHUh?=
NCI-H1648 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnOUos3UUN3ME2yNlkvPDh7IN88US=> NGj4UZBUSU6JRWK=
ES6 M{PMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvnfoxKSzVyPUKzPU41OyEQvF2= M2S2enNCVkeHUh?=
KNS-81-FD MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vVVmlEPTB;MkSxMlE6PyEQvF2= MnjlV2FPT0WU
JAR NFTtXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXZ2lEPTB;MkW2MlIzPSEQvF2= Moq4V2FPT0WU
NB1 NYXlWYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmwNGZzUUN3ME2yOlAvPTF4IN88US=> NUC2OJA3W0GQR1XS
D-336MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;HN|V7UUN3ME2yOlAvPjl6IN88US=> MkLvV2FPT0WU
BC-3 M{G4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ4NT6xO|gh|ryP MXLTRW5ITVJ?
HCC2218 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ4Nj60NVUh|ryP MlrzV2FPT0WU
TE-9 NIjwOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorkTWM2OD1{Nk[uOlI4KM7:TR?= MULTRW5ITVJ?
LB1047-RCC MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ4Nj63OVMh|ryP M37Pc3NCVkeHUh?=
CTB-1 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HuXWlEPTB;Mk[5Mlk4OyEQvF2= NXT3ZpFNW0GQR1XS
NB7 M1z6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLaTWM2OD1{N{Gg{txO NWmzcHdKW0GQR1XS
ST486 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjN[npoUUN3ME2yO|cvPDF{IN88US=> NHfSPWxUSU6JRWK=
HCC1187 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\De3dKSzVyPUK4Nk45OTFizszN NUjHTZo1W0GQR1XS
NCI-SNU-16 M{TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ6ND6yOFgh|ryP MoHMV2FPT0WU
COR-L279 NX;RcYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW5b45KSzVyPUK5NU42QDRizszN MmK2V2FPT0WU
ES8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ7ND6xPFIh|ryP NEjGZlBUSU6JRWK=
U-698-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ7OD6yOFMh|ryP M3\YT3NCVkeHUh?=
HEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHaWVJKSzVyPUOwPU4yPDlizszN NV;URpVIW0GQR1XS
KINGS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n4bGlEPTB;M{GwMlY4PCEQvF2= M3XjSXNCVkeHUh?=
KY821 NGj3[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSz[lNjUUN3ME2zN|YvPTl3IN88US=> M4jlZ3NCVkeHUh?=
MZ1-PC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofOTWM2OD1|NEWuOlE5KM7:TR?= NEO3fnJUSU6JRWK=
LS-411N NHrIV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DyVmlEPTB;M{W0MlY3KM7:TR?= M2TtRXNCVkeHUh?=
SIG-M5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[yeJNKSzVyPUO1PU44QDJizszN NFW3[FFUSU6JRWK=
HT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TDXmlEPTB;M{[3MlcyOSEQvF2= NHm3TnhUSU6JRWK=
HC-1 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzkVVN7UUN3ME2zOlcvPzh5IN88US=> NXHEOpRiW0GQR1XS
NCI-H1694 M2m5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD1|N{KuPVM1KM7:TR?= M4X0PXNCVkeHUh?=
BB65-RCC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrsdo9KSzVyPUO3Ok4zPDVizszN NYH4NGF2W0GQR1XS
HAL-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQRnI{UUN3ME2zO|kvQDN6IN88US=> NUO1cYp{W0GQR1XS
ARH-77 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL6SGp1UUN3ME2zPVQvODB6IN88US=> NUXVcHlPW0GQR1XS
MZ7-mel MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zbG5{UUN3ME2zPVcvOjN|IN88US=> NF\lPXJUSU6JRWK=
SIMA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRyMz65N|Mh|ryP MnzIV2FPT0WU
DG-75 M1fncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ucWJKSzVyPUSxOU43QThizszN M1TUeXNCVkeHUh?=
HUTU-80 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XsdmlEPTB;NEG5MlE5PSEQvF2= NE\JbmlUSU6JRWK=
KNS-42 NWLyb4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfvc21KSzVyPUSyOU45OTVizszN M1fxO3NCVkeHUh?=
SH-4 NFjNcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXDTGZTUUN3ME20NlcvPTZ3IN88US=> M2OzWXNCVkeHUh?=
L-540 NX3hPIRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmzO|BKSzVyPUSzNU4xOzFizszN NF7WSGtUSU6JRWK=
NB10 NGDtXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3[JpLUUN3ME20OFEvOjN2IN88US=> MWTTRW5ITVJ?
ES1 M2PMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXLOnJKSzVyPUS1Nk44PTNizszN NF;OfXhUSU6JRWK=
KMOE-2 M1WzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zu[WlEPTB;NEW2MlcyOSEQvF2= MXLTRW5ITVJ?
MC116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HDOmlEPTB;NEW4MlEyPiEQvF2= MX3TRW5ITVJ?
RCC10RGB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq3foRKSzVyPUS2NE4xODVizszN NEfHdmlUSU6JRWK=
RL95-2 M4D2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi5V4ZKSzVyPUS2NE4zOzdizszN MUPTRW5ITVJ?
Raji NVnie|liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\jNmJPUUN3ME20OlgvOTR|IN88US=> MonRV2FPT0WU
CAS-1 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\YTWM2OD12N{KuNFc{KM7:TR?= MULTRW5ITVJ?
Calu-6 M3e3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTR5NT6yOlUh|ryP NH;JU2VUSU6JRWK=
KG-1 NUjnZohjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPOTWM2OD12N{iuOFQh|ryP MWPTRW5ITVJ?
LB771-HNC NUTvSFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjTWM2OD12OEKuNlMzKM7:TR?= M{O5SHNCVkeHUh?=
ACN NH7YcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR7Mz61PVkh|ryP MYrTRW5ITVJ?
KM12 M2XWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXnSmdiUUN3ME20PVYvPTh7IN88US=> NVzrS5Z1W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL (24.29 mM) warming
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO <1 mg/mL
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID